SynthesisBMC anesthesiology2026
Efficacy and safety of stellate ganglion block for postoperative pain management: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStellate ganglion block (SGB) is a form of regional anesthesia employed to reduce postoperative pain management. This meta-analysis assesses its efficacy and safety for postoperative pain control.
methodsWe conducted a comprehensive search of PubMed, Embase, Cochrane Library, and Web of Science covering all records up to September 20,2025 to identify eligible randomized controlled trials (RCTs). Stata 15.0 software was applied for data analysis, and RevMan 5.4 was employed to assess the risk of bias.
resultsA total 33 RCTs comprising 2231 participants were included, SGB may reduce pain at 6[SMD=-1.35, 95%CI(-1.96, -0.73)], 12[SMD=-1.09, 95%CI(-1.83, -0.35)]and 24[SMD=-1.03, 95%CI(-1.56, -0.20)] hours postoperatively, whereas no significant difference was observed at 48 h and postoperative total opioid consumption [SMD = - 0.55, 95% CI (- 1.24, 0.13)] and and ICU stays [MD=-0.37, 95% CI(- 0.95, 0.21)]. It shortened hospital stay [MD = - 1.04, 95% CI (- 1.74, - 0.34)], reduced the incidence of postoperative nausea and vomiting[RR = 0.55, 95% CI (0.40, 0.77)], but the incidence of upper eyelid ptosis was markedly higher than in the control group [RR = 31.67, 95% CI (6.43, 155.90)].
conclusionsStellate ganglion block may help alleviate early pain (6, 12, and 24 h) postoperatively, It also shortens hospital and the ICU stays and reduces the incidence of nausea and vomiting but increases the incidence of upper eyelid ptosis. Analysis showed no significant group-to-group differences in other indicators. Given the limitations of the included studies, further high-quality, large-sample randomized controlled trials are needed to confirm and expand upon the efficacy and safety of stellate ganglion block.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.